Article

Pediatric Mental Health Care Dysfunction Disorder?

Hastings Center, Garrison, NY, USA.
New England Journal of Medicine (Impact Factor: 54.42). 05/2010; 362(20):1853-5. DOI: 10.1056/NEJMp1003175
Source: PubMed
Download full-text

Full-text

Available from: Erik Parens, Aug 01, 2015
0 Followers
 · 
107 Views
  • Source
    • "Mood-stabilizing and antipsychotic medications have been used for pediatric BP (Delbello, Schwiers, Rosenberg, & Strakowski, 2002; Findling et al., 2009; Tohen et al., 2007) and increasingly are used off-label to treat irritability and aggression. It has been proposed that the lack of evidencebased interventions for SMD has contributed to the high rates of polypharmacy in children, especially among those with ADHD (Comer et al., 2010; Olfson, Crystal, Huang, & Gerhard, 2010; Parens et al., 2010). There has been little systematic research documenting their effectiveness in youth with SMD who do not have a formal mood disorder (IMS Health, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: No psychosocial treatments have been developed for children with ADHD and severe mood dysregulation (SMD) despite the significant prevalence and morbidity of this combination. Therefore, the authors developed a novel treatment program for children with ADHD and SMD. Method: The novel therapy program integrates components of cognitive-behavioral therapies for affect regulation with a parent-training intervention for managing recurrent defiant behaviors. It consists of nine 105-min child and parent groups run in unison. A pilot trial was conducted with seven participants with ADHD and SMD ages 7 to 12 who were on a stable stimulant regimen. Results: Six of the seven (86%) families completed the program. Participants showed large improvements in depressive symptoms, mood lability, and global functioning. Milder improvements in externalizing behaviors were observed. Conclusion: Results suggest the feasibility and potential efficacy of the therapy program for children with ADHD and SMD and warrant a larger controlled trial. (J. of Att. Dis. 2012; XX(X) 1-XX).
    Journal of Attention Disorders 02/2012; 17(6). DOI:10.1177/1087054711433423 · 2.40 Impact Factor
  • Source
    The Hastings Center Report 41(2):S1-32. · 1.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Not Available
    OCEANS '89. Proceedings; 10/1989
Show more